HUP0203303A3 - Compositions for administering taxanes orally to human patients - Google Patents

Compositions for administering taxanes orally to human patients

Info

Publication number: HUP0203303A3
Authority: HU; Hungary
Prior art keywords: compositions; human patients; administering taxanes; taxanes orally; orally
Prior art date: 1999-10-27

Application number

HU0203303A

Other languages

Hungarian (hu)

Original Assignee

Baker Norton Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-27

Filing date

2000-10-27

Publication date

2005-01-28

2000-10-27 Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma

2003-02-28 Publication of HUP0203303A2 publication Critical patent/HUP0203303A2/en

2005-01-28 Publication of HUP0203303A3 publication Critical patent/HUP0203303A3/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Immunology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HU0203303A 1999-10-27 2000-10-27 Compositions for administering taxanes orally to human patients HUP0203303A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16231099P	1999-10-27	1999-10-27
PCT/US2000/029633 WO2001030448A1 (en)	1999-10-27	2000-10-27	Method and compositions for administering taxanes orally to human patients

Publications (2)

Publication Number	Publication Date
HUP0203303A2 HUP0203303A2 (en)	2003-02-28
HUP0203303A3 true HUP0203303A3 (en)	2005-01-28

Family

ID=22585092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0203303A HUP0203303A3 (en)	1999-10-27	2000-10-27	Compositions for administering taxanes orally to human patients

Country Status (18)

Country	Link
EP (1)	EP1225956A1 (en)
JP (1)	JP2003512443A (en)
KR (1)	KR20030019296A (en)
CN (1)	CN1450923A (en)
AU (1)	AU1104201A (en)
BR (1)	BR0015149A (en)
CA (1)	CA2389583A1 (en)
CO (1)	CO5251425A1 (en)
CZ (1)	CZ20021484A3 (en)
HU (1)	HUP0203303A3 (en)
IL (1)	IL149360A0 (en)
MX (1)	MXPA02004164A (en)
NO (1)	NO20022008L (en)
PL (1)	PL354777A1 (en)
RU (1)	RU2002113659A (en)
SK (1)	SK5822002A3 (en)
WO (1)	WO2001030448A1 (en)
ZA (1)	ZA200203358B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6750246B1 (en)	2000-02-03	2004-06-15	Bristol-Myers Squibb Company	C-4 carbonate taxanes
WO2002043765A2 (en)	2000-11-28	2002-06-06	Transform Pharmaceuticals, Inc.	Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2002357012A1 (en) *	2001-11-27	2003-06-10	Transform Pharmaceuticals, Inc.	Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
CA2504268A1 (en) *	2002-10-30	2004-11-18	Spherics, Inc.	Nanoparticulate bioactive agents
US7345093B2 (en)	2004-04-27	2008-03-18	Formatech, Inc.	Methods of enhancing solubility of compounds
US7659310B2 (en)	2004-04-27	2010-02-09	Formatech, Inc.	Methods of enhancing solubility of agents
AR050043A1 (en) *	2004-08-03	2006-09-20	Novartis Ag	METHODS TO IMPROVE BIODISPONIBILITY AND PHARMACEUTICAL COMPOSITION FOR CARDIOVASCULAR DISORDERS
CN101513395B (en) *	2008-02-20	2011-01-12	单宝华	Taxol double-layer soft capsule oral preparation medicament
US10143652B2 (en)	2009-09-23	2018-12-04	Curirx Inc.	Methods for the preparation of liposomes
CA2781527C (en)	2009-09-23	2017-10-24	Indu Javeri	Methods for the preparation of liposomes
EP2566474B1 (en)	2010-05-03	2017-11-15	Teikoku Pharma USA, Inc.	Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (en)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	Non-aqueous taxane nanodispersion formulations and methods of using the same
JO3737B1 (en) *	2015-07-21	2021-01-31	Athenex Therapeutics Ltd	Therapeutic combinations of orally administered paclitaxel and a P-gp inhibitor for the treatment of cancer
EP4059497A1 (en) *	2021-03-17	2022-09-21	Dompé farmaceutici S.p.a.	C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
CA3212816A1 (en) *	2021-03-17	2022-09-22	Dompe' Farmaceutici Spa	C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6964946B1 (en) *	1995-10-26	2005-11-15	Baker Norton Pharmaceuticals, Inc.	Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) *	1996-01-31	1997-08-07	Steven B. Hansel	A method of making pharmaceutically active taxanes orally bioavailable
WO1997048689A1 (en) *	1996-06-17	1997-12-24	Eli Lilly And Company	Drug resistance and multidrug resistance modulators
CN1261275A (en) *	1997-05-27	2000-07-26	巴克·诺顿药物有限公司	Method and compositions for administering taxanes orally to human patients
GB9718903D0 (en) *	1997-09-05	1997-11-12	Glaxo Group Ltd	Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU756752B2 (en) *	1998-04-01	2003-01-23	Skyepharma Canada Inc.	Anticancer compositions
EP1178786A4 (en) *	1999-05-21	2006-03-01	American Bioscience Inc	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

2000
- 2000-10-27 MX MXPA02004164A patent/MXPA02004164A/en unknown
- 2000-10-27 JP JP2001532859A patent/JP2003512443A/en active Pending
- 2000-10-27 EP EP00972373A patent/EP1225956A1/en not_active Withdrawn
- 2000-10-27 KR KR1020027005396A patent/KR20030019296A/en not_active Application Discontinuation
- 2000-10-27 RU RU2002113659/15A patent/RU2002113659A/en not_active Application Discontinuation
- 2000-10-27 IL IL14936000A patent/IL149360A0/en unknown
- 2000-10-27 CA CA002389583A patent/CA2389583A1/en not_active Abandoned
- 2000-10-27 AU AU11042/01A patent/AU1104201A/en not_active Abandoned
- 2000-10-27 PL PL00354777A patent/PL354777A1/en not_active Application Discontinuation
- 2000-10-27 WO PCT/US2000/029633 patent/WO2001030448A1/en not_active Application Discontinuation
- 2000-10-27 CN CN00815924A patent/CN1450923A/en active Pending
- 2000-10-27 CZ CZ20021484A patent/CZ20021484A3/en unknown
- 2000-10-27 CO CO00082131A patent/CO5251425A1/en not_active Application Discontinuation
- 2000-10-27 SK SK582-2002A patent/SK5822002A3/en unknown
- 2000-10-27 BR BR0015149-1A patent/BR0015149A/en not_active IP Right Cessation
- 2000-10-27 HU HU0203303A patent/HUP0203303A3/en unknown
2002
- 2002-04-26 NO NO20022008A patent/NO20022008L/en not_active Application Discontinuation
- 2002-04-26 ZA ZA200203358A patent/ZA200203358B/en unknown

Also Published As

Publication number	Publication date
CA2389583A1 (en)	2001-05-03
PL354777A1 (en)	2004-02-23
CZ20021484A3 (en)	2003-12-17
NO20022008L (en)	2002-06-19
JP2003512443A (en)	2003-04-02
SK5822002A3 (en)	2003-01-09
AU1104201A (en)	2001-05-08
MXPA02004164A (en)	2002-10-17
IL149360A0 (en)	2002-11-10
HUP0203303A2 (en)	2003-02-28
EP1225956A1 (en)	2002-07-31
CO5251425A1 (en)	2003-02-28
NO20022008D0 (en)	2002-04-26
CN1450923A (en)	2003-10-22
ZA200203358B (en)	2003-04-29
KR20030019296A (en)	2003-03-06
BR0015149A (en)	2002-10-29
RU2002113659A (en)	2004-01-27
WO2001030448A1 (en)	2001-05-03

Publication	Publication Date	Title
HUP0202495A3 (en)	2004-05-28	Stable medicinal compositions for oral use
HUP0203437A3 (en)	2003-07-28	Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
PL356358A1 (en)	2003-04-07	Solid dosage form of someticone for oral administration
HUP0002512A3 (en)	2001-03-28	Medicinal compositions for application to mucosa
HK1149719A1 (en)	2011-10-14	Ciclesonide contained pharmaceutical composition for application to mucosa
HUP0203303A3 (en)	2005-01-28	Compositions for administering taxanes orally to human patients
AU3469400A (en)	2000-07-24	Pharmaceutical compositions for treatment of diseased tissues
HUP0203311A3 (en)	2004-06-28	New pharmaceutical compositions of prolonged effect
HUP0003546A3 (en)	2002-12-28	Compositions for administering taxanes orally to human patients
IL145559A0 (en)	2002-06-30	Tolperison-containing pharmaceutical preparation for oral administration
GB2355656B (en)	2004-04-07	Pharmaceutical compositions for oral and topical administration
HUP0104963A3 (en)	2002-11-28	Compositions for the treatment of skin diseases
HUP0102159A3 (en)	2004-01-28	Pharmaceutical composition for the treatment of rumen acidosis
IL166337A0 (en)	2006-01-16	Oral administration of calctionin
HUP0201667A2 (en)	2002-09-28	Oral form of administration
AU1732401A (en)	2001-06-18	Medicinal compositions for oral use
IL149422A0 (en)	2002-11-10	Oral pharmaceutical compositions for liver therapy
HUP0400495A3 (en)	2007-05-02	Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
GB9910865D0 (en)	1999-07-07	Improvements relating to medical syringes
EP1210935A4 (en)	2005-02-02	Medicinal compositions for oral use
HUP0200311A3 (en)	2002-12-28	Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions
AU2002229468A1 (en)	2002-06-18	Oral capsule for administering tablets to animals
EP1188440A4 (en)	2004-04-14	Medicinal composition for oral administration
HUP9903735A3 (en)	2001-02-28	Use of indazolo derivatives for producing pharmaceutical compositions for treatment heart failure
GB9930266D0 (en)	2000-02-09	Oral administration of beneficial substances